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ABSTRACT
Good’s syndrome is a relatively rare
immunodeficiency condition that presents in
the fourth or fifth decade of life and is defined
by hypogammaglobulinemia in the setting of a
thymoma. The humoral defect may be severe
enough to cause an absence in B cells, with a
consequent recurrence of sinopulmonary
disease, chronic non-infectious diarrhea and
opportunistic infections. The prognosis in
patients with Good’s syndrome appears to be
worse than in those with X-linked
agammaglobulinemia (XLA) and common
variable immune deficiency (CVID). There
have only been three cases of Good’s
syndrome associated with mycobacterium, and
only one case with a cavitary lesion in the
lungs. We present here a unique case of Good’s
syndrome with a non-mycobacterial cavitary
lesion.





Good’s syndrome is a relatively rare
immunodeficiency condition that presents in
the fourth or fifth decade of life and is defined
by hypogammaglobulinemia in the setting of a
thymoma [1]. The humoral defect may be severe
enough to cause an absence in B cells, with a
consequent recurrence of sinopulmonary
disease, chronic non-infectious diarrhea, and
opportunistic infections. The prognosis in
patients with Good’s syndrome appears to be
worse than in those with X-linked
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agammaglobulinemia (XLA) and common
variable immune deficiency (CVID) [2]. In a
case series of 240 patients, the 5-year survival
rate was almost 100% for patients with XLA and
CVID, compared to 70% for patients with
Good’s syndrome. The 10-year survival rate
dropped to 33% in Good’s syndrome patients,
compared to 95% for patients with XLA and
CVID [3]. Morbidity and mortality in Good’s
syndrome is attributable to secondary processes
such as infections, autoimmunity and
hematological dysfunction, rather than the
thymoma itself.
There have only been three cases of Good’s
syndrome associated with mycobacterium, and
only one case with a cavitary lesion in the lungs
[4, 5]. We present here a unique case of Good’s
syndrome with a non-mycobacterial cavitary
lesion.
CASE PRESENTATION
A 56-year-old Ethiopian male immigrant was
admitted with persistent fever and chills,
cough, night sweats, and weight loss. He had a
past medical history significant for a type A
thymoma that was resected 3 years prior to
admission. An outpatient pulmonologist who
had seen him for suspected tuberculosis referred
him to the Inpatient Medicine Unit following a
computed tomography (CT) scan of the chest
that revealed a 3.5 cm right hilar region mass.
There were also two additional smaller adjacent
nodules in the right lower lobes, and scattered
areas of tree and bud nodularity.
The patient was subsequently admitted to
Ronald Reagan UCLA Medical Center and
placed on respiratory isolation. Here, he
reported a history of fatigue and dyspnea on
exertion, as well as recurrent sinopulmonary
infections that intermittently responded to
antibiotics. These infections often recurred in
the setting of irritable bowel syndrome D (IBS-
D) symptoms, hallmarked by diarrhea.
At the time of admission, he had a low-grade
fever with otherwise normal vital signs and
oxygen saturation on room air. Blood tests were
significant for an absolute lymphocyte count of
1,000 cells/lL, and hemoglobin of 11.7 g/dL.
The only other abnormalities were decreases in
albumin and protein levels.
A chest CT scan on admission revealed an
irregular, cavitating soft-tissue right hilar mass
involving the posterior segment of the right
upper lobe and superior segment of the right
lower lobe. In addition, there were focal areas of
mucous impaction and bronchiectasis with
multiple diffuse scattered clusters of
bronchocentric micronodules, many in a tree-
in-bud nodularity (Fig. 1).
Cultures of blood, sputum and urine were
negative for an extensive workup that included
human immunodeficiency virus (HIV),
cytomegalovirus (CMV), acid-fast bacillus,
Histoplasma, Aspergillus and
coccidioidomycosis. Finally, a biopsy of the
cavitary lesion of the lung showed ulceration
with acute and chronic inflammation. Cultures
from a transbronchial biopsy were negative.
Grocott’s methenamine silver (GMS) staining
was negative for fungal organisms, and there
was no evidence of malignancy.
On the second day of hospitalization,
induced sputum was positive for Pneumocystis
jiroveci and Moraxella catarrhalis. Given the
history of recurrent pneumonia, lymphopenia
and an opportunistic infection in the setting of
a HIV negative patient, a more thorough
immunologic workup was performed. As
shown in Table 1, low levels of CD3 (540/
cmm) and CD4 (250/cmm) T cells were found,
while CD8 (264/cmm), and CD16&56 (93/
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cmm) were normal. The B cell lineage was
profoundly deficient, starting with CD19
(1/cmm), and carried through with
immunoglobulin M (IgM) (\5 mg/dL), IgA
(20 mg/dL), and IgG (176 mg/dL); he showed
no antibody response to any of the 14
pneumococcal serotypes examined.
Furthermore, a lymphocyte proliferation assay
demonstrated a significantly decreased response
to tetanus and candida, as compared to a
normal control.
The patient was subsequently treated for
pneumonia with sulfamethoxazole/
trimethoprim double strength for 3 weeks
followed by sulfamethoxazole/trimethoprim
single strength for prophylaxis. He was also
started on monthly intravenous
immunoglobulin (IVIG) replacement, which
was continued after discharge. Over 6 months
following discharge the patient remains free of
hospitalization, reporting a reversal of his
dyspnea, and a drastic improvement in his
quality of life. He continues to be monitored
for anemia, as there have been reported cases of
Good’s syndrome with pure red cell aplasia
[6, 7].
Informed consent was obtained from the
patient for being included in the study.
Fig. 1 Computed tomography (CT) scan of the chest with a right hilar region mass, mucous impaction and bronchiectasis







CD3 540/cmm (841–2,402) 86% (59–86)
CD4 250/cmm (355–1,426) 42% (29–62)
CD8 264/cmm (255–1,090) 45% (16–41)
CD19 1/cmm (10–590) \1% (7–25)
CD16&56
(NK cells)
93/cmm (71–477) 15% (4–19)
Immunoglobulins Level (normal range)
IgA 20 mg/dL (80–400)
IgG 176 mg/dL (690–1,660)
IgM \5 mg/dL (37–318)
CD cluster of differentiation, Ig immunoglobulin, NK
natural killer
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DISCUSSION
The 2005 practice parameters define Good’s
syndrome as a subset of CVID [8]; however, the
reduced number of peripheral B cells seen in
Good’s syndrome is not a feature of CVID,
where only impairment in B cell maturation is
usually observed. Diagnosis remains based on
clinical criteria. However, genetic analysis has
begun to elucidate the etiology of Good’s
syndrome, which, like CVID, appears to affect
proteins involved in the proliferation and
differentiation of B cells [9, 10]. In a
systematic review of 152 patients with Good’s
syndrome, 42% of patients were diagnosed with
thymoma prior to being diagnosed with
hypogammaglobulinemia, infection or
diarrhea, while in 38% of patients the
diagnoses were made almost simultaneously—
i.e., within 2 months of each other [2]. Since
10% of patients diagnosed with a thymoma
continue to develop hypogammaglobulinemia,
an immunologic workup at regular intervals can
be very helpful in preventing opportunistic
infections. Additionally, patients with
hypogammaglobulinemia should be screened
for thymoma, as 10% will continue to present
with a thymoma [2]. Good’s syndrome shares
many features with CVID, but unlike the latter
and the more serious XLA, it carries a much
worse prognosis. Aside from the additional
involvement of thymic dysfunction, one of
the reasons for inferior outcomes is the greater
delay in diagnosis [11].
In contrast to other humoral immune
defects, patients with this syndrome can
develop opportunistic infections, and the
prognosis appears less favorable compared
with XLA or CVID [3]. Immunological workup,
including T cell subsets, B cells and quantitative
immunoglobulins, should be considered as part
of the routine diagnostic evaluation in patients
with a thymoma and recurrent infections.
It is important to note that Good’s syndrome
may progress even after thymectomy and
corticosteroid treatment [12, 13]. However,
early recognition and treatment with
antibiotics or immunoglobulin replacement
can change the natural course of this rare
condition, and prove to be successful in
keeping the patient symptom free [14].
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